Future studies should delineate the progression features that are directly regulated by Nrg4 in adipocytes and determine whether this phenotype is reproducible in other insulin-sensitive tissues, such as the liver and skeletal muscle to provide new pharmacological targets to prevent or reverse metabolic diseases. The gene discussed is INS; the disease is metabolic disease.